Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.

The Journal of antimicrobial chemotherapy - 1 Jan 2013

Asahchop Eugene L, Oliveira Maureen, Quashie Peter K, Moisi Daniela, Martinez-Cajas Jorge L, Brenner Bluma G, Tremblay Cecile L, Wainberg Mark A

Abstract excerpt

OBJECTIVES: HIV-1 protease inhibitors (PIs) are key components of HIV therapy. PL-100 is a novel lysine sulphonamide that demonstrates potent antiviral activity against multiresistant HIV-1 strains as well as a higher genetic barrier for development of resistance mutations compared with first-generation PIs. In the present study, we compared the antiviral activity of PL-100 against HIV-1 subtype B with that of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Mutation

Share to Structure-Activity Relationship

Share to Sulfonamides

Source

Identifiers

PMID: 22945918
DOI: 10.1093/jac/dks342

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.PMID 22945918Read ↗

In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.Semantic proximity Read ↗

C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.Semantic proximity Read ↗

A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active SiteSemantic proximity Read ↗

Comprehending the Structure, Dynamics, and Mechanism of Action of Drug-Resistant HIV ProteaseSemantic proximity Read ↗

Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.Semantic proximity Read ↗

Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.Semantic proximity Read ↗

Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance.Semantic proximity Read ↗

Molecular docking-based screening for novel inhibitors of the human immunodeficiency virus type 1 protease that effectively reduce the viral replication in human cellsSemantic proximity Read ↗

Current and Novel Inhibitors of HIV ProteaseSemantic proximity Read ↗

TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.Semantic proximity Read ↗

Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.Semantic proximity Read ↗

Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.